Aclaris Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $496.72M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $1.60M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $2.00M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $1.30M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $3.30M | $-0.12 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | $1.80M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $1.50M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | Before market open | $9.20M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | Before market open | $4.30M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | Before market open | $2.80M | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | During market hours | $2.40M | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 27, 2024 | Before market open | $17.60M | – | – |
Press releases
Announcements Aclaris Therapeutics filed with the SEC
Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Results of operations · EX-99.1 to Form 8-K
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Results of operations · EX-99.1 to Form 8-K
ATI-052: Full SAD MAD Results
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,”
Regulation FD disclosure · EX-99.1 to Form 8-K
Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4R α Bispecific Antibody ATI-052 Supporting Expedited Clinical Development
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Highly Potent and Bioactive Investigational
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Developing Therapeutic Franchises to Address Gaps
Regulation FD disclosure · EX-99.1 to Form 8-K
Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
ATI-2138 Phase 2a Top-Line Results
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
June 2025 EMPOWERING PATIENTS THROUGH
Regulation FD disclosure · EX-99.1 to Form 8-K
Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
May 2025 EMPOWERING PATIENTS THROUGH
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
I N V E S T O R
Regulation FD disclosure · EX-99.1 to Form 8-K
Aclaris Therapeutics Announces Exclusive, Global License Agreement
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aclaris Therapeutics Announces $80 Million Private Placement
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
© Copyright 2024 Aclaris Therapeutics, Inc. All rights reserved Confidential © Copyright 2024 Aclaris Therapeutics, Inc. All rights reserved
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Aclaris Therapeutics Announces Sale of OLUMIANT ® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
© Copyright 2024 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX)
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Aclaris Therapeutics Provides Corporate Update
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor
Regulation FD disclosure · EX-99.1 to Form 8-K
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX)
Regulation FD disclosure · EX-99.2 to Form 8-K
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX)
Regulation FD disclosure · EX-99.1 to Form 8-K
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K